Table 2.
Univariate analysis and multivariate Cox regression analysis of clinical factors influencing overall survival outcomes in the training cohort
| Variable | Univariate analysis, p value | Multivariate analysis, HR (95% CI) | p value |
|---|---|---|---|
| Sex, male | 0.238 | ||
| Age, years | 0.148 | ||
| Hypertension | 0.804 | ||
| Diabetes | 0.334 | ||
| Hepatitis B | 0.022 | 0.324 | |
| Liver cirrhosis | 0.032 | 0.015 | |
| Absent | ref | ||
| Present | 2.227 (1.169–4.242) | ||
| Hypersplenism | 0.888 | ||
| ALT, IU/L | 0.582 | ||
| AST, IU/L | 0.750 | ||
| ALB, g/L | 0.650 | ||
| TBIL, μmol/L | 0.831 | ||
| PT, s | 0.247 | ||
| INR | 0.480 | ||
| AFP level, ng/mL | 0.696 | ||
| CA 125 level, U/mL | 0.083 | 0.839 | |
| CA 19-9 level | 0.003 | < 0.001 | |
| < 35 U/mL | ref | ||
| ≥ 35 U/mL | 3.984 (2.146–7.407) | ||
| CEA level | 0.172 | ||
| Tumor size | 0.007 | 0.006 | |
| ≤ 5 cm | ref | ||
| > 5 cm | 2.293 (1.263–4.167) | ||
| Differentiation | 0.409 |
Abbreviations: HR Hazard ratio, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ALB Albumin, TBIL Total bilirubin, PT Prothrombin time, INR International normalized ratio, AFP Alpha fetoprotein, CA Carbohydrate antigen, CEA Carcinoembryonic antigen, ref Reference